A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Kymab investigational site 8806, Changhua

Kymab investigational site 3602, Budapest

Kymab investigational site 3601, Nyíregyháza

Kymab investigational site 3906, Candiolo

Kymab investigational site 3908, Turin

Kymab investigational site 1108, Orlando

Kymab investigational site 1104, Sarasota

Kymab investigational site 1103, Nashville

Kymab investigational site 3904, Meldola

Kymab investigator site 1101, Houston

Kymab investigational site 1109, Duarte

Kymab investigational site 1102, New Haven

Kymab investigational site 3901, Milan

Kymab investigational site 3903, Milan

Kymab investigational site 3902, Napoli

Kymab investigational site 3910, Roma

Kymab investigational site 8801, Taipei

Kymab investigational site 4405, London

Kymab investigational site 4402, Manchester

Kymab investigational site 4404, Oxford

Kymab investigational site 4401, Sutton

Kymab investigational site 4801, Siedlce